Dr. Brooks explains the association between male sex and 5-FU exposure. Nivolumab plus ipilimumab showed significant improvement in progression-free survival in patients in the first line setting. Dr. Abdilleh discusses PanCAN's new cloud-based data and analytics program for pancreatic cancer research. Dr. Amit Mahipal discusses liquid biopsy for advanced cholangiocarcinoma and how it compares to tissue-based testing. Dr. Ethan Ludmir discusses the phase II EXTEND trial on MDT with systemic therapy for pancreatic ductal adenocarcinoma. Dr. Elizabeth Conner offers insight on how DCP can be utilized as a biomarker for treatment response in patients with HCC. Dr. Lieu discusses the CIRCULATE-NORTH AMERICA trial on ctDNA status as a biomarker for risk stratification in colon cancer. Dr. Brown discussed the results of a retrospective analysis on the addition of radiation to atezolizumab and bevacizumab. Dr. Yelena Janjigian discusses the results of the phase 3 MATTERHORN study at ASCO GI 2024. Dr. Milind Javle discusses tinengotinib monotherapy in patients with metastatic cholangiocarcinoma at ASCO GI 2024. Dr. Christopher Lieu gives an overview of some of the top presentations and data to look out for at ASCO GI 2024. Dr. Julien Calderaro explains the potential of AI to serve as a biomarker of sensitivity to atezolizumab plus bevacizumab. Drs. Vijayvergia and Lieu conclude with considerations for managing IO-related toxicities in patients with metastatic HCC. Drs. Vijayvergia and Lieu continue their discussion with attention to biomarkers of response for immunotherapy in mHCC. Drs. Vijayvergia and Lieu detail the considerations for administering immunotherapy to their patients with metastatic HCC. Drs. Llovet and Finn consider how LEAP-002 adds to the debate around IO/VEGF, IO/IO, and IO/TKI for aHCC. Drs. Llovet and Finn provide a high-level understanding of LEAP-002, looking at lenvatinib/pembrolizumab for 1L aHCC. Drs. Lidsky and Eng discuss PUMP, a phase 3 trial of HAI for treating patients with CRC and unresectable liver metastases. Drs. Mahipal and Finn share the safety and prognostic considerations for patients with aHCC receiving lenvatinib after IO. Drs. Mahipal and Finn discuss real-world outcomes for hepatocellular carcinoma patients receiving lenvatinib following IO.